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In 1960, Alphonse Chapanis, turned his attention from 
engineering to health care. In a study of medication-
related errors in a 1100-bed hospital,1 he and his 
colleague identified seven sources of such errors 
potentially leading to harm to a patient: medicine 
omitted, or given to the wrong patient, at the wrong 
dose, as an unintended extra dose, by the wrong route, 
at the wrong time, or as the wrong drug entirely. Almost 
60 years later, these same types of errors still happen 
worldwide. Later that year in a follow-up policy paper,2 
Chapanis identified four areas of recommendations 
that could prevent harm and remain relevant today: 
written communication, medication procedures, the 
working environment, training, and education. Indeed, 
it is difficult to avoid the conclusion that had the 
recommendations from this revelatory patient safety 
research been assiduously followed over the past five 
decades, hundreds of thousands fewer patients would 
have been killed or seriously harmed by the medicines 
intended to make them well.
Beginning in 2004, WHO, working in partnership with 
the then World Alliance for Patient Safety, initiated two 
Global Patient Safety Challenges, Clean Care is Safer 
Care3 and Safe Surgery Saves Lives.4 These challenges 
mobilised worldwide commitment and action to reduce 
health-care-associated infections and risk associated with 
surgery, respectively. At the second Global Summit of 
Health Ministers on Patient Safety in Bonn, Germany, on 
March 29, 2017, the Director-General of WHO announced 
that the Third Global Patient Safety Challenge, Medication 
Without Harm, would address medication safety.5 
The previous challenges secured strong and early 
commitment from health ministers, professional bodies, 
regulators, health leaders, civil society, and health-care 
practitioners. The action required to deliver the goals of 
each was broadly similar: an evidence-based analysis of 
the key problems and solutions; an invitation to WHO 
member states and other relevant parties to pledge, or 
sign-up, to address the aims of the challenge; high-profile 
actions to generate passion and enthusiasm; facilitation 
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of implementation by the WHO secretariat and 
associated experts and advisers; and strong leadership 
and extensive internal and external communication. 
Formal evaluations of impact and outcome were more 
complex to undertake, but studies that were done gave 
encouraging results.6,7 For example, Clean Care is Safer 
Care eventually secured ministerial pledges that covered 
85% of the world’s population. This campaign took on 
many of the characteristics of a social movement.
Now the Third Global Patient Safety Challenge seeks the 
commitment of health ministers, health-system leaders, 
and a range of stakeholders, including educational 
institutions, experts, medicines regulators, researchers, 
pharmaceutical companies, patient representative 
bodies, and professional organisations. Its goal will be 
to reduce the level of severe, avoidable harm related to 
medications by 50% over 5 years, globally.
The action will fall into three categories. First, countries 
will be asked to target three priority areas: high-risk 
situations, polypharmacy, and transitions of care. Second, 
health ministries will be invited to convene experts in 
their countries to design specific programmes of action 
for improving safety in each of four domains in which 
a medications can cause inadvertant harm: health care 
professionals’ behaviour; systems and practices of 
medication; medicines; patients and the public. Third, 
WHO will use its global convening and advocacy role to 
pursue successful outcomes in a range of areas, including: 
strengthening the quality of data to monitor medication-
related harm; providing guidance and developing 
strategies, plans, and tools to ensure that the medication 
process has the safety of patients at its core in all health-
care settings; producing a strategy for setting out 
research priorities; monitoring and evaluating the impact 
of the challenge; continuing to engage with regulatory 
agencies and international actors to improve medication 
safety through improved packaging and labelling; and 
designing tools and technologies that empower patients 
to safely manage their own medications. 
Health ministers who commit to address this challenge 
will be invited to designate a national coordinator 
to spearhead the Global Patient Safety Challenge on 
Medication Without Harm in their country. Excellent 
professional leadership will be crucial for success. 
Throughout the implementation process, WHO will also 
seek to emphasise the special problems of medication-
related harm in low-income and middle-income countries. 
Worldwide, medication errors cost an estimated 
US$42 billion annually.8 This is 0·7% of the total global 
health expenditure.8 A conservative estimate by the US 
Institute of Medicine, in 2007, gave the total additional 
annual cost of treating hospitalised patients in the USA 
as $3·5 billion.9 This serious source of avoidable harm 
and death has stalked health care since it was clearly 
delineated 60 years ago. The time to stop it is long 
overdue.
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